A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA studyShun Lü, Weiguo Su, Zhendong Chen et al.|Lung Cancer|2020Cited by 21
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS studyQing Zhou, Yi‐Long Wu, Helong Zhang et al.|Journal of Cancer Research and Clinical Oncology|2023Cited by 9
Correction: Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor SignalingTao Wang, Ke Chen, Wen Song et al.|Clinical Cancer Research|2022Cited by 1